Cargando…

Microbial Modulation of Coagulation Disorders in Venous Thromboembolism

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in the world. Important risk factors of thrombosis include bed restraint, surgery, major trauma, long journeys, inflammation, pregnancy, and oral contrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichota, Anna, Gwozdzinski, Krzysztof, Szewczyk, Eligia M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406375/
https://www.ncbi.nlm.nih.gov/pubmed/32801832
http://dx.doi.org/10.2147/JIR.S258839
_version_ 1783567406214414336
author Lichota, Anna
Gwozdzinski, Krzysztof
Szewczyk, Eligia M
author_facet Lichota, Anna
Gwozdzinski, Krzysztof
Szewczyk, Eligia M
author_sort Lichota, Anna
collection PubMed
description Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in the world. Important risk factors of thrombosis include bed restraint, surgery, major trauma, long journeys, inflammation, pregnancy, and oral contraceptives, previous venous thromboembolism, cancer, and bacterial infections. Sepsis increases the risk of blood clot formation 2–20 times. In this review, we discussed various mechanisms related to the role of bacteria in venous thrombosis also taking into consideration the role of the human microbiome. Many known bacteria, such as Helicobacter pylori, Chlamydia pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli, causing infections may increase the risk of thrombotic complications through platelet activation or may lead to an inflammatory reaction involving the fibrinolytic system. Additionally, the bacteria participate in the production of factors causing or increasing the risk of cardiovascular diseases. An example can be trimethylamine N-oxide (TMAO) but also uremic toxins (indoxyl sulfate), short-chain fatty acids (SCFA) phytoestrogens, and bile acids. Finally, we presented the involvement of many bacteria in the development of venous thromboembolism and other cardiovascular diseases.
format Online
Article
Text
id pubmed-7406375
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74063752020-08-14 Microbial Modulation of Coagulation Disorders in Venous Thromboembolism Lichota, Anna Gwozdzinski, Krzysztof Szewczyk, Eligia M J Inflamm Res Original Research Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in the world. Important risk factors of thrombosis include bed restraint, surgery, major trauma, long journeys, inflammation, pregnancy, and oral contraceptives, previous venous thromboembolism, cancer, and bacterial infections. Sepsis increases the risk of blood clot formation 2–20 times. In this review, we discussed various mechanisms related to the role of bacteria in venous thrombosis also taking into consideration the role of the human microbiome. Many known bacteria, such as Helicobacter pylori, Chlamydia pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli, causing infections may increase the risk of thrombotic complications through platelet activation or may lead to an inflammatory reaction involving the fibrinolytic system. Additionally, the bacteria participate in the production of factors causing or increasing the risk of cardiovascular diseases. An example can be trimethylamine N-oxide (TMAO) but also uremic toxins (indoxyl sulfate), short-chain fatty acids (SCFA) phytoestrogens, and bile acids. Finally, we presented the involvement of many bacteria in the development of venous thromboembolism and other cardiovascular diseases. Dove 2020-07-30 /pmc/articles/PMC7406375/ /pubmed/32801832 http://dx.doi.org/10.2147/JIR.S258839 Text en © 2020 Lichota et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lichota, Anna
Gwozdzinski, Krzysztof
Szewczyk, Eligia M
Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
title Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
title_full Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
title_fullStr Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
title_full_unstemmed Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
title_short Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
title_sort microbial modulation of coagulation disorders in venous thromboembolism
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406375/
https://www.ncbi.nlm.nih.gov/pubmed/32801832
http://dx.doi.org/10.2147/JIR.S258839
work_keys_str_mv AT lichotaanna microbialmodulationofcoagulationdisordersinvenousthromboembolism
AT gwozdzinskikrzysztof microbialmodulationofcoagulationdisordersinvenousthromboembolism
AT szewczykeligiam microbialmodulationofcoagulationdisordersinvenousthromboembolism